Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anthracycline-based Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1: a Prospective, Randomized, Controlled Phase III Clinical Trial

NCT06744504 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06744504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06744504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anthracycline-based Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1: a Prospective, Randomized, Controlled Phase III Clinical Trial
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 3
Overall status
Recruiting
Start date
January 10, 2025
Completion date
December 1, 2029
Enrollment
284 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, runx1-runx1t1 fusion protein expression